Steve Eppler

Clinical pharmacokinetics of bevacizumab in patients with solid tumors

Jianfeng Lü, René Bruno, Steve Eppler et al. · Cancer Chemotherapy and Pharmacology · 2008 · 343 citations

Oncology, Medicine, Pharmacotherapy +3

Clinical pharmacokinetics of erlotinib in patients with solid tumors and exposure-safety relationship in patients with non–small cell lung cancer

Jianfeng Lü, Steve Eppler, J WOLF et al. · Clinical Pharmacology & Therapeutics · 2006 · 223 citations

Pharmacokinetics of Ranibizumab in Patients with Neovascular Age-Related Macular Degeneration: A Population Approach

Lu Xu, Tong Lu, Lisa Tuomi et al. · Investigative Ophthalmology & Visual Science · 2013 · 196 citations

Evaluation of the Absolute Oral Bioavailability and Bioequivalence of Erlotinib, an Inhibitor of the Epidermal Growth Factor Receptor Tyrosine Kinase, in a Randomized, Crossover Study in Healthy Subjects

Paul Frohna, Jianfeng Lu, Steve Eppler et al. · The Journal of Clinical Pharmacology · 2006 · 109 citations

Oral Bioavailability, Healthy Subjects, Pharmacological Study +14

Phase I Dose-Escalation Study of Onartuzumab as a Single Agent and in Combination with Bevacizumab in Patients with Advanced Solid Malignancies

Ravi Salgia, Premal H. Patel, John Bothos et al. · Clinical Cancer Research · 2014 · 65 citations · Full text